Navigation Links
Genenews adds two members to its Board of Directors
Date:5/5/2008

TORONTO, May 5 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), a company focused on developing blood-based biomarker tests for the early detection of diseases and personalized health management, today announced its shareholders recently elected two additional members to its Board of Directors, Mr. Harry A. Glorikian and Ms. Fran Tuttle. They join Mr. Rory Riggs, Mr. James Howard-Tripp, Mr. Garth MacRae, Dr. Heiner Dreismann, Dr. C. C. Liew and Dr. K. Wayne Marshall on the Company's Board of Directors.

"We are pleased to welcome Mr. Glorikian and Ms. Tuttle to the GeneNews Board of Directors. Mr. Glorikian is currently the managing partner of Scientia Advisors, an international management and strategy consulting firm with a concentration in biotechnology and life sciences and Ms. Tuttle is President and Chief Executive Officer of HX Diagnostics, a diagnostics company in Emeryville, Ca., specialising in rapid diagnostics for seasonal and emerging infectious diseases," said K. Wayne Marshall, MD, PhD, President and Chief Executive Officer of GeneNews. "Their extensive experience in molecular diagnostics makes them timely additions to our Board as we prepare for the commercialization of our laboratory developed test (LDT) version of ColonSentry(TM), a blood-based molecular test to assess current risk for colorectal cancer. We expect to launch ColonSentry in Canada in the third quarter of this year."

Prior to becoming the Managing Partner at Scientia Advisors, Mr. Glorikian spent more than 8 years at Applied Biosystems in various roles, completing his tenure as Senior Manager, New Technology Assessment/Business Development. He was also the National Sales Manager for Signet Laboratories and a founder of X-Cell Laboratories, a clinical reference laboratory in San Francisco.

Ms. Tuttle is currently the President and CEO of HX Diagnostics. Throughout her career, she has developed and launched several major diagnostics products and had corporate experience at leading diagnostic companies including Bayer, Corning, Inc., Novartis, and Chiron. Ms. Tuttle was a Senior Vice President at Bayer Diagnostics responsible for a worldwide business of $400M. Most recently Ms. Tuttle was President and CEO of Protedyne, Inc., a robotics company developing automation solutions for molecular diagnostics and drug discovery, which was sold to LabCorp in 2007.

About GeneNews

--------------

GeneNews is focused on the application of functional genomics to enable early diagnosis and personalized therapeutic intervention based on disease-specific biomarkers. The Company has developed a novel approach, the Sentinel Principle(TM), to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle(TM) in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' first product in development, ColonSentry(TM), is a convenient and patient-friendly blood-based test that can assess an individual's current risk for colorectal cancer. For more information on GeneNews, visit http://www.genenews.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE GeneNews Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. GeneNews CSO Dr. CC Liew awarded state honour by the Government of Malaysia
2. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
3. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
4. GeneNews receives ISO 13485 accreditation
5. GeneNews selected to present late-breaking abstract at AACR Annual Meeting
6. GeneNews announces 2007 year end results
7. GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR
8. GeneNews Announces First Quarter Results
9. KGI Elects Three New Members to Board of Trustees
10. The Pittsburgh Life Sciences Greenhouse Elects Four New Members to Its Board of Directors
11. Stiefel Laboratories Appoints Two New Members to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , December 8, 2016 ... expanded its customisable SureSeqâ„¢ NGS panel range with the launch ... fast and cost-effective study of variants in familial hypercholesterolemia (FH). ... variation (CNV) detection on a single small panel and allows ... content. This includes all exons for LDLR , ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... flexible packaging for their exceptionally efficient human mesenchymal stem/stromal cell (hMSC) expansion ... of bioprocess media products engineered to radically streamline culture processes, minimize processing ...
(Date:12/8/2016)...  Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... and commercializing products to treat rare diseases where ... the long-term follow-up data from its Phase 2 ... Defense Regulator (IDR), in the treatment of oral ... undergoing chemoradiation therapy (CRT).  The additional 12-month safety ...
(Date:12/8/2016)... , Dec. 8, 2016 Savannah ... remediation technologies and selected NewTechBio,s NT-MAX Lake ... microbial based beneficial bacteria, in conjunction with Hexa ... correct deficiencies with National Pollutant Discharge Elimination System ... has experienced a steady history of elevated pH ...
Breaking Biology Technology:
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
(Date:12/2/2016)... AUSTIN, Texas , Dec. 1, 2016 /PRNewswire/ ... provider, today announced BioLock , an electrocardiogram ... and health monitoring, a key IoT asset. The ... embedded into a vehicle,s steering wheel and mobile ... a simple touch. As vehicle technology ...
(Date:11/29/2016)... , November 29, 2016 Nearly one billion ... Continue Reading ... ... part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The ...
Breaking Biology News(10 mins):